Outlook Therapeutics, Inc. filings document material events for a Nasdaq-listed biopharmaceutical company focused on ONS-5010/LYTENAVA for wet AMD and other retina-disease applications. The company’s 8-K disclosures cover FDA-related communications for its biologics license application, including Complete Response Letter follow-up, Type A meeting activity and formal dispute-resolution matters.
Regulatory filings also describe capital-structure activity involving common stock, warrants, registered and unregistered securities, note financing and amendments to debt instruments. Governance records include shareholder voting results, board composition changes, proxy-related matters, Nasdaq-listed common stock information, exhibits and risk-factor or material-agreement disclosures tied to financing and regulatory developments.
Outlook Therapeutics director Kurt J. Hilzinger received two equity awards reported on 10/01/2025 and 10/03/2025. The filings show a stock option for 286,734 shares priced at $1.04 that vests in full on 10/01/2026 with acceleration on a Change in Control, and a stock option for 90,638 shares priced at $1.06 granted in lieu of $85,000 cash fees that vest in four equal quarterly installments ending 09/30/2026, also subject to Change in Control acceleration. Both option grants are held directly by the reporting person and have an expiration date of 10/01/2035 or 10/03/2035 respectively. The report was filed by one reporting person and signed by an attorney-in-fact on 10/03/2025.
Outlook Therapeutics director Julian S. Gangolli was granted a non‑employee director stock option on 10/01/2025 to buy 286,734 shares of common stock at an exercise price of $1.04 per share. The option is an annual grant under the company’s Non‑Employee Director Compensation Policy and the 2024 Equity Incentive Plan. The option shall fully vest on 10/01/2026 provided the director continues service through that date, and the underlying shares are subject to acceleration on a Change in Control if the director is in service immediately before such event. The filing was reported on Form 4 and signed by an attorney‑in‑fact on behalf of the reporting person.
Outlook Therapeutics, Inc. (OTLK) director Yezan Munther Haddadin reported two option grants. On 10/01/2025 he was granted 286,734 stock options with a $1.04 exercise price that, per the issuer, "shall fully vest on October 1, 2026" subject to continuous service and acceleration on a Change in Control. On 10/03/2025 he received 95,969 options with a $1.06 exercise price granted in lieu of $90,000 in cash fees; these vest in four equal quarterly installments and become fully vested on September 30, 2026, subject to continuous service and similar Change in Control acceleration. Both option grants expire in 2035 and are reported as direct beneficial ownership. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Outlook Therapeutics (OTLK) reported a director equity award on Form 4. The reporting person received a stock option for 286,734 shares at an exercise price of $1.04 on 10/01/2025. According to the disclosure, this annual grant under the 2024 Equity Incentive Plan vests in full on 10/01/2026, with potential acceleration upon a Change in Control.
A separate stock option for 58,648 shares at an exercise price of $1.06 was granted on 10/03/2025 in lieu of $55,000 of cash director fees. These options vest in four equal quarterly installments, fully vested by 09/30/2026, and are also subject to acceleration upon a Change in Control under the plan terms.
Outlook Therapeutics, Inc. (OTLK) reported stock option grants to director Faisal G. Sukhtian consisting of 286,734 options at an exercise price of $1.04 (grant date 10/01/2025) and 117,296 options at $1.06 (grant date 10/03/2025), for a total of 404,030 options. The first grant is an annual non-employee director award that fully vests on 10/01/2026 subject to continued service and accelerates upon a Change in Control. The second grant was issued in lieu of $110,000 in cash fees and vests in four equal quarterly installments, fully vesting on 09/30/2026, subject to continued service and Change in Control acceleration.
Outlook Therapeutics, Inc. reported that it has completed a requested Type A meeting with the U.S. Food and Drug Administration regarding the complete response letter dated August 27, 2025 for its biologics license application resubmission for ONS-5010, an investigational ophthalmic formulation of bevacizumab for wet age-related macular degeneration. Based on this discussion and the FDA’s feedback, the company now expects to resubmit its BLA before the end of calendar year 2025. These details were disclosed through a press release dated September 29, 2025 that is filed as an exhibit.
Outlook Therapeutics, Inc. reported that Chief Commercial Officer Jeff Evanson stepped down from his role effective September 5, 2025. His departure is treated as a termination of employment without “cause” under his executive employment agreement and other company plans. Subject to his signing and not revoking a separation agreement that includes a release of claims against the company, he will receive severance benefits consistent with the terms provided for a termination without cause. The company states that a description of these severance benefits is contained in its Definitive Proxy Statement filed on February 10, 2025, which is incorporated by reference.
Outlook Therapeutics, Inc. reported that the U.S. Food and Drug Administration issued a complete response letter to its biologics license application for ONS-5010, an investigational ophthalmic formulation of bevacizumab being developed to treat wet age-related macular degeneration (wet AMD). A complete response letter means the FDA has finished its review but has decided that the application cannot be approved in its current form. The company disclosed this development through a press release, which is included as an exhibit to the report.
Great Point Partners, LLC together with Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl report beneficial ownership of 2,220,000 shares of Outlook Therapeutics, Inc. common stock, representing 4.99% of the outstanding shares based on 42,192,728 shares reported by the issuer. The holdings consist of warrants to purchase 2,220,000 shares, which are treated as beneficially owned but are subject to an exercise restriction (a Beneficial Ownership Cap) that prevents exercise if it would increase ownership above 9.99%.
The reporting persons disclose shared voting and dispositive power over the 2,220,000 shares and state the position is not held to influence control of the issuer. The filing is a joint Schedule 13G/A and includes a Joint Filing Agreement executed August 14, 2025.
Outlook Therapeutics, Inc. (OTLK) reports commercial availability of LYTENAVA (bevacizumab gamma) in Europe in fiscal 2025 and recognizes revenue when product is delivered to pharmaceutical wholesalers, with returns, rebates and administrative fees contractually applied. The company has 260,000,000 shares authorized and reported 43,479,051 shares issued and outstanding at June 30, 2025 versus 23,905,635 at September 30, 2024.
The filing details multiple financing transactions in 2025 including a public offering that generated net proceeds of $11,625,229, ATM capacity with $88,301,796 remaining as of June 30, 2025, and several warrant inducement transactions that produced net proceeds and resulted in mark-to-market and inducement charges (including $27,711,889 and $4,196,868 recorded for the nine months ended June 30, 2025). The company notes a March 2025 Note with conversion mechanics, high default interest (22% per annum) and potential dilution triggers. A securities class action is pending and a motion to dismiss is under review.